Liminal BioSciences Pulls Plug On Its Lead Development Program
Liminal BioSciences Inc (NASDAQ:LMNL) will discontinue the development of fezagepras based on results from the Phase 1a single ascending dose (SAD)…
Liminal BioSciences Reports First Subject Dosed In Phase 1a Single Ascending Dose Trial Of Fezagepras
Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the Company's Phase 1a single ascending dose
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Liminal BioSciences Outlines Plans To Further Develop Its Lead Compound
Liminal BioSciences Inc (NASDAQ:LMNL) has provided an update on plans for further developing its lead compound fezagepras. The announcement follows the…
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it
Liminal BioSciences Outlines 2022 Strategic Priorities
Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for